T1	Drug 31 55	MF59-containing vaccines
T2	Drug 62 67	Fluad
T3	Drug 72 80	Addigrip
T4	Drug 85 118	virosome-based influenza vaccines
T5	Drug 127 137	Inflexal V
T6	Drug 140 154	InfectoVac Flu
T7	Drug 159 166	Invivac
T8	Temporal 168 205	during the 2006-2007 influenza season
*	OR T6 T7 T5
T9	Scope 127 167	Inflexal V™, InfectoVac Flu™ or Invivac™
R1	Subsumes Arg1:T4 Arg2:T9	
T10	Scope 62 81	Fluad™ or Addigrip™
*	OR T2 T3
R2	Subsumes Arg1:T1 Arg2:T10	
*	OR T1 T4
T11	Scope 31 167	MF59-containing vaccines, e.g. Fluad™ or Addigrip™ or virosome-based influenza vaccines such as Inflexal V™, InfectoVac Flu™ or Invivac™
R3	Has_temporal Arg1:T11 Arg2:T8	
T12	Temporal 244 258;317 349	within 2 weeks prior to enrolment in this study
T13	Temporal 244 250;289 296;317 349	within 4 weeks prior to enrolment in this study
T14	Drug 264 284	inactivated vaccines
A1	Optional T14
R4	Has_temporal Arg1:T14 Arg2:T12	
T15	Drug 302 315	live vaccines
A2	Optional T15
R5	Has_temporal Arg1:T15 Arg2:T13	
*	OR T14 T15
T16	Drug 226 243	licensed vaccines
T17	Scope 244 349	within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study
R6	Has_scope Arg1:T16 Arg2:T17	
T18	Drug 380 387	vaccine
T19	Qualifier 392 422	foreseen by the study protocol
T20	Negation 388 391	not
*	OR T19 T20
R7	Has_qualifier Arg1:T18 Arg2:T19	
T21	Temporal 423 436	up to 30 days
T22	Drug 454 465	vaccination
T23	Value 447 453	second
R8	AND Arg1:T23 Arg2:T22	
T24	Drug 471 483	H5N1 vaccine
R9	AND Arg1:T22 Arg2:T24	
R10	Has_value Arg1:T21 Arg2:T23	
R11	Has_temporal Arg1:T18 Arg2:T21	
T25	Temporal 521 538	more than 14 days
T26	Qualifier 486 493	Chronic
T27	Drug 543 561	immunosuppressants
R13	Subsumes Arg1:T26 Arg2:T25	
T28	Drug 565 593	other immune-modifying drugs
T29	Temporal 594 617	within six months prior
T30	Scope 543 593	immunosuppressants or other immune-modifying drugs
R12	Has_qualifier Arg1:T30 Arg2:T26	
R14	Has_temporal Arg1:T30 Arg2:T29	
T31	Condition 696 713;733 742	immunosuppressive condition
T32	Condition 717 742	immunodeficient condition
*	OR T32 T31
T33	Qualifier 673 682	confirmed
T34	Qualifier 686 695	suspected
*	OR T33 T34
T35	Scope 673 695	confirmed or suspected
T36	Scope 696 742	immunosuppressive or immunodeficient condition
R15	Has_scope Arg1:T36 Arg2:T35	
T37	Condition 840 867	chronic alcohol consumption
T38	Condition 875 885	drug abuse
*	OR T37 T38
T39	Observation 829 836	History
T40	Scope 840 885	chronic alcohol consumption and/or drug abuse
R16	Has_scope Arg1:T39 Arg2:T40	
T41	Condition 899 927	hypersensitivity to vaccines
T42	Observation 888 895	History
R17	AND Arg1:T42 Arg2:T41	
T43	Condition 941 957	allergic disease
T44	Condition 941 949;961 970	allergic reactions
*	OR T44 T43
T45	Observation 930 937	History
T46	Scope 1039 1065	egg and thiomersal allergy
T47	Condition 1039 1042;1058 1065	egg allergy
T48	Condition 1047 1065	thiomersal allergy
T49	Scope 941 970	allergic disease or reactions
R18	Subsumes Arg1:T49 Arg2:T46	
R19	Has_scope Arg1:T45 Arg2:T49	
T51	Condition 1109 1123;1142 1164	cardiovascular functional abnormality
T52	Condition 1125 1132;1142 1164	hepatic functional abnormality
T53	Condition 1136 1164	renal functional abnormality
T50	Condition 1098 1107;1142 1164	pulmonary functional abnormality
*	OR T50 T51 T52 T53
T54	Condition 1236 1249	Acute disease
T55	Temporal 1250 1274	at the time of enrolment
R20	Has_temporal Arg1:T54 Arg2:T55	
T56	Condition 1337 1354;1418 1426	chronic pulmonary disorder
T57	Condition 1337 1344;1356 1370;1418 1426	chronic cardiovascular disorder
T58	Condition 1337 1344;1372 1377;1418 1426	chronic renal disorder
T59	Condition 1337 1344;1379 1391;1418 1426	chronic neurological disorder
T60	Condition 1337 1344;1393 1404;1418 1426	chronic psychiatric disorder
T61	Condition 1337 1344;1408 1426	chronic metabolic disorder
*	OR T56 T57 T58 T59 T60 T61
T62	Drug 1506 1521	immunoglobulins
T63	Drug 1529 1547	any blood products
*	OR T62 T63
T64	Temporal 1548 1603	within the three months preceding the first vaccination
T65	Scope 1506 1547	immunoglobulins and/or any blood products
T66	Condition 1821 1830	condition
T67	Qualifier 1831 1836;1874 1926	which prevents the subject from participation in the study
R22	Has_qualifier Arg1:T66 Arg2:T67	
T68	Non-representable 1838 1872	in the opinion of the investigator
R23	AND Arg1:T67 Arg2:T68	
T69	Non-representable 1817 1927	Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.
T70	Qualifier 1637 1652	investigational
T71	Qualifier 1656 1670	non-registered
*	OR T70 T71
T72	Drug 1671 1678	product
T73	Scope 1637 1670	investigational or non-registered
R24	Has_scope Arg1:T72 Arg2:T73	
T74	Drug 1680 1684	drug
T75	Drug 1688 1695	vaccine
*	OR T74 T75
T76	Scope 1680 1695	drug or vaccine
R25	Subsumes Arg1:T72 Arg2:T76	
T77	Negation 1697 1707	other than
T78	Drug 1712 1728	study vaccine(s)
R26	Has_negation Arg1:T78 Arg2:T77	
T79	Qualifier 1697 1728	other than the study vaccine(s)
R27	Has_qualifier Arg1:T72 Arg2:T79	
R28	multi Arg1:T79 Arg2:T78	
T80	Temporal 1729 1774	within 30 days prior to the first vaccination
R29	Has_temporal Arg1:T72 Arg2:T80	
T81	Reference_point 1753 1774	the first vaccination
T82	Procedure 1763 1774	vaccination
T83	Temporal 1757 1762	first
R30	Has_temporal Arg1:T82 Arg2:T83	
R31	multi Arg1:T81 Arg2:T82	
R32	Has_index Arg1:T80 Arg2:T81	
T84	Mood 1779 1786	planned
T85	Temporal 1791 1814	during the study period
T86	Procedure 1787 1790	use
R33	Has_mood Arg1:T86 Arg2:T84	
R34	Has_temporal Arg1:T86 Arg2:T85	
R35	AND Arg1:T72 Arg2:T86	
T87	Qualifier 1277 1284	Serious
T88	Condition 1285 1300	chronic disease
R36	Has_qualifier Arg1:T88 Arg2:T87	
T89	Scope 1337 1426	chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder
R37	Subsumes Arg1:T88 Arg2:T89	
T90	Temporal 1607 1623	during the study
T91	Reference_point 1582 1603	the first vaccination
T92	Procedure 1592 1603	vaccination
T93	Temporal 1586 1591	first
R38	Has_temporal Arg1:T92 Arg2:T93	
R39	multi Arg1:T91 Arg2:T92	
R40	Has_index Arg1:T64 Arg2:T91	
T94	Scope 1548 1623	within the three months preceding the first vaccination or during the study
*	OR T64 T90
R21	Has_scope Arg1:T65 Arg2:T94	
T95	Reference_point 1614 1623	the study
R41	Has_index Arg1:T90 Arg2:T95	
